Skip to main content
placeholder image

Brexpiprazole joins growing group of approved antipsychotics: what does our early experience say?

Journal Article


Abstract


  • Background: The skepticism that implies that most

    placebo-controlled studies are conducted by the

    pharmaceutical industry and are not to be trusted is

    pervasive. Published randomized controlled trials provide

    a comprehensive picture of short-term efficacy and

    tolerability in relation to placebo, but in the absence of realworld

    clinical experience it is difficult to predict whether

    the new drug has meaningful advantages or disadvantages

    compared with existing agents.

    Objectives: To present an experiential narrative account

    of patients trialled on brexpiprazole as a part of patient

    familiarization program (PFP) and early clinical experience.

    Methods: Longitudinal follow-up patients initiated on

    brexpiprazole with different clinical dimensions and

    heterogeneity will be discussed.

    Findings: Our experience suggest that brexpiprazole is

    well tolerated, with a favorable safety profile that does

    not exhibit significant rates of important adverse events

    that can be seen with existing antipsychotics (akathisia,

    sedation, weight gain or QTc prolongation), and therefore

    may provide a useful treatment option for patients with

    schizophrenia.conclusions: Clinical trial results add layers to

    our knowledge and experience as clinicians. While

    acknowledging the limitations of experiential descriptive,

    it helps us reflect on the effectiveness of antipsychotics

    under naturalistic clinical conditions; its results should

    have particular applicability to clinical practice. At least,

    experiential descriptive helps us to address the needs

    of individual practitioners seeking to make good clinical

    decisions for individual patients.

Publication Date


  • 2018

Citation


  • Pai, N. B. (2018). Brexpiprazole joins growing group of approved antipsychotics: what does our early experience say?. Australian and New Zealand Journal of Psychiatry, 52 (S1), 147.

Start Page


  • 147

Volume


  • 52

Issue


  • S1

Place Of Publication


  • United Kingdom

Abstract


  • Background: The skepticism that implies that most

    placebo-controlled studies are conducted by the

    pharmaceutical industry and are not to be trusted is

    pervasive. Published randomized controlled trials provide

    a comprehensive picture of short-term efficacy and

    tolerability in relation to placebo, but in the absence of realworld

    clinical experience it is difficult to predict whether

    the new drug has meaningful advantages or disadvantages

    compared with existing agents.

    Objectives: To present an experiential narrative account

    of patients trialled on brexpiprazole as a part of patient

    familiarization program (PFP) and early clinical experience.

    Methods: Longitudinal follow-up patients initiated on

    brexpiprazole with different clinical dimensions and

    heterogeneity will be discussed.

    Findings: Our experience suggest that brexpiprazole is

    well tolerated, with a favorable safety profile that does

    not exhibit significant rates of important adverse events

    that can be seen with existing antipsychotics (akathisia,

    sedation, weight gain or QTc prolongation), and therefore

    may provide a useful treatment option for patients with

    schizophrenia.conclusions: Clinical trial results add layers to

    our knowledge and experience as clinicians. While

    acknowledging the limitations of experiential descriptive,

    it helps us reflect on the effectiveness of antipsychotics

    under naturalistic clinical conditions; its results should

    have particular applicability to clinical practice. At least,

    experiential descriptive helps us to address the needs

    of individual practitioners seeking to make good clinical

    decisions for individual patients.

Publication Date


  • 2018

Citation


  • Pai, N. B. (2018). Brexpiprazole joins growing group of approved antipsychotics: what does our early experience say?. Australian and New Zealand Journal of Psychiatry, 52 (S1), 147.

Start Page


  • 147

Volume


  • 52

Issue


  • S1

Place Of Publication


  • United Kingdom